Virtual Library
Start Your Search
E. Wingate
Author of
-
+
P2.14 - Radiotherapy (ID 715)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Radiotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.14-013 - Effect of Stereotactic Radiotherapy (SABR) on Pulmonary Function and Quality of Life: Results from a Tertiary Oncology Unit (ID 9076)
09:30 - 09:30 | Author(s): E. Wingate
- Abstract
Background:
Surgical resection is generally accepted as the gold standard for managing early stage lung cancer. There remains, however, a subset of patients who do not proceed to surgery. Many of these patients are ‘medically inoperable’ due to comorbidities. Others may decline surgery or their tumour is deemed inoperable due to technical difficulties. In this subset, SABR has been shown to be an effective alternative treatment option. SABR involves multiple beams, which together deliver an ablative dose of radiation to a precise area. There is rapid dose fall-off which ensures sparing of nearby structures. Evidence suggests that SABR is not associated with a clinically relevant deterioration in quality of life (QoL). The negative impact on pulmonary function is also minimal. This audit aims to assess the effect of SABR on both pulmonary function and QoL of a cohort of patients undergoing treatment in the West Midlands.
Method:
The Queen Elizabeth Hospital, Birmingham delivers SABR to patients across the West Midlands. We followed a cohort of 45 patients who received SABR between September 2016 and April 2017 for early stage lung cancer. If patients had baseline PFTs, these were repeated between 3-13 weeks post treatment. Patients had their QoL assessed using the EORTC Quality of Life Questionnaire (QLQ-C30 version 3). This was recorded at baseline, early and late follow up (defined as 13-28 days and 30-75 days post treatment respectively).
Result:
To date, twenty patients have had baseline FEV1 and FVC which was repeated post treatment. Median baseline FEV1 was 1.52 (range 0.56-2.92) and median baseline FVC was 2.63 (range 1.25-4.89). Post treatment median FEV1 was 1.34 (range 0.60-2.61) and median FVC was 2.42 (range 1.40- 3.95). Using a Wilcoxon Signed Ranks test, there was no significant difference between pre and post treatment FEV1 or FVC (Z=-0.78,p=0.43 and Z=-1.0,p=0.31 respectively). Similarly, there was no difference in DLCO pre and post treatment (Z= -0.27,p=0.79) Thirty nine patients had their baseline QoL assessed. Of these, 36 had this repeated at early follow-up and 31 at late follow up. Median QoL score at baseline, early and late follow up was 66/100, 54/100 and 50/100 respectively. There was no significant difference in either early or late QoL compared to baseline (Z=-0.49,p=0.63 and Z=-0.15,p=0.88).
Conclusion:
Overall this study shows no significant difference in either PFTs or QoL in this cohort of patients undergoing SABR in Birmingham. These results compare favourably with other published data and are reassuring for our practice
